TAP Pharmaceuticals

From Infogalactic: the planetary knowledge core
Jump to: navigation, search


TAP Pharmaceuticals was an American pharmaceutical company headquartered in Lake Forest, IL. It was a joint venture formed in 1977 between Abbott Laboratories and the Japanese pharmaceutical company Takeda. The joint venture was dissolved in 2008 and most of the company merged with Takeda.

TAP had several marketed products selling within the United States:

History

"Fourteen years ago, TAP had 200 employees. Today, the company has grown to more than 3,300 employees. As TAP evolves and grows to meet the needs of customers, the challenge will be to maintain the energy and optimism that makes TAP unique. Ultimately, it is not the size of the company that matters—TAP's success will be measured by how well the company meets the challenge of serving patients. TAP believes that the best way to meet that challenge is to live and work by its mission and the Spirit of TAP.

Throughout TAP's history, its efforts have been focused on developing and bringing innovative treatments to the people who need them. LUPRON INJECTION (leuprolide acetate), TAP's first product, was the first new hormonal therapy for the palliative treatment of advanced prostate cancer in 40 years. Prevacid (lansoprazole), a proton pump inhibitor (PPI), quickly became one of the most widely prescribed therapies for acid-related disease in North America. And the focus on innovation continues as the people of TAP work to improve patient convenience with new dosing and packaging advancements, research new indications for existing products, and develop new products in the pipeline." [1]

Timeline

1977

Takeda Chemical Industries, Ltd. and Abbott form a joint research partnership, Takeda-Abbott Products (TAP).

1985

LUPRON INJECTION (leuprolide acetate) approved by FDA for palliative treatment of advanced prostate cancer, the first new hormonal treatment for prostate cancer in 40 years.

1989

Lupron Depot 7.5 mg approved for palliative treatment of advanced prostate cancer.

1990

Lupron Depot 3.75 mg approved for management of endometriosis.

1993

Lupron Depot-PED (leuprolide acetate for depot suspension) approved for treatment of central precocious puberty.

1994

TAPCare introduced.

1995

Prevacid approved by FDA for short-term treatment of erosive esophagitis, active duodenal ulcers and pathological hypersecretory conditions. Lupron Depot 3.75 approved, in combination with iron, for presurgical treatment of anemia caused by uterine fibroids. Lupron Depot-3 Month 22.5 mg approved for palliative treatment of advanced prostate cancer. CaPSURETM introduced.

1996

Prevacid approved for long-term maintenance of healed erosive esophagitis.

The Prevacid launch becomes one of the most successful in pharmaceutical history.


1997

Prevacid approved for short-term treatment of active benign gastric ulcers and maintenance of healed duodenal ulcer. Prevacid in combination with clarithromycin and amoxicillin approved for 14-day therapy for eradication of H. pylori to reduce the risk of duodenal ulcer recurrence.

Prevpac blister packaging approved for 14-day triple therapy for eradication of H. pylori to reduce the risk of duodenal ulcer recurrence.

Lupron Depot-3 Month 11.25 mg approved for treatment of endometriosis and, in combination with iron, for presurgical treatment of anemia caused by uterine fibroids.

Lupron Depot-4 Month 30 mg approved for palliative treatment of advanced prostate cancer.

1998

Prevacid approved for short-term treatment of symptomatic gastroesophageal reflux disease and, in combination with clarithromycin and amoxicillin, for 10-day therapy for eradication of H. pylori to reduce the risk of duodenal ulcer recurrence.

1999

Prevpac (lansoprazole/amoxicillin/clarithromycin) 10-day triple therapy approved for eradication of H. pylori to reduce the risk of duodenal ulcer recurrence. Prevacid approved for new administration options, including sprinkling on cottage cheese, yogurt or Ensure pudding or strained pears, as well as mixing with orange juice and tomato juice. NDA filed with FDA for Spectracef.

2000

Prevacid becomes the first PPI approved by the FDA for the treatment and risk reduction of recurrence of NSAID-associated (nonsteroidal anti-inflammatory drug) gastric ulcers in chronic NSAID users. TAP enters a long-term research collaboration with IPF PharmaCeuticals GmbH.

2001

TAP settled serious criminal and civil charges in the United States in 2001 as a result of two whistleblower cases.[2] TAP enters co-promotion agreement with Unimed/Solvay Pharmaceuticals for AndroGel 1% (testosterone gel). TAP enters collaborative research agreement with Ligand Pharmaceuticals. Spectracef approved by FDA. Lupron Depot add-back therapy approved by FDA. Prevacid is the first PPI approved in a packet for oral suspension.

2002

Prevacid becomes available through Together RxTM, an innovative program from members of the pharmaceutical industry to provide prescription medication discounts for seniors without prescription drug insurance coverage.

2003

TAP introduces Prevacid NapraPACTM (lansoprazole delayed release capsules and naproxen tablet kit) a first of its kind combination package containing two widely used medications in one prescription. TAP introduces Lupron Depot (leuprolide acetate for depot suspension) with LuproLocTM, making Lupron Depot the first product in its class to offer a needlestick safety device on its prefilled syringes.

TAP ends agreement with Unimed/Solvay Pharmaceuticals to co-promote Androgel, 1% (testosterone gel).

TAP returns rights to Spectracef (cefditoren pivoxil) to partner Meiji Seika Kaisha, Ltd. of Japan.

2004

TAP names new management team of Alan MacKenzie, President and Glenn Warner, Executive Vice President. TAP submits New Drug Application(NDA) to the U.S. Food and Drug Administration(FDA) for febuxostat for the management of hyperuricemia in chronic gout. The U.S. FDA approves several new options for patients using Prevacid:

  • Labeling for use of Prevacid in adolescents aged 12 to 17.
  • New dosing options for Prevacid(lansoprazole) SoluTabTM Orally Disintegrating Tablets.
  • Prevacid I.V.(lansoprazole) for Injection was approved for use in the treatment of erosive esophagitis in hospitalized patients.

2008

Takeda Pharmaceutical Company Limited announced on July 1, 2008 that Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. merged with TAP Pharmaceutical Products Inc. (TAP), forming one of the top 15 pharmaceutical companies in the United States.[3]

The merger is a result of the conclusion of a 30-year joint venture between Takeda Pharmaceutical Company Limited and Abbott Laboratories, which was announced on March 19, 2008. According to terms previously announced, Takeda received the rights to TAP’s product Prevacid, its non-Lupron related commercial organization, TAP's support organizations, and TAP’s pipeline, and Abbott received the rights to Lupron.[3]

References

  1. ↑ From the company website's history page, accessed 2007-05-29
  2. ↑ Taxpayers Against Fraud Press Release, Settlement of $875 million Medicare/Medicaid drug fraud yields new funds for trust fund and could deter overcharging, October 3, 2001. http://www.phillipsandcohen.com/2001/Settlement-of-875-million-Medicare-Medicaid-drug-fraud-yields-new-funds-for-trust-fund-and-could-deter-overcharging.shtml
  3. ↑ 3.0 3.1 Press Release: Takeda, Abbott Announce Plans to Conclude TAP Joint Venture March 20, 2008

External links

Retrieved from "https://infogalactic.com/w/index.php?title=TAP_Pharmaceuticals&oldid=2846917"